ES2291981T3 - Moduladores del receptor de la vitamina d. - Google Patents

Moduladores del receptor de la vitamina d. Download PDF

Info

Publication number
ES2291981T3
ES2291981T3 ES04819516T ES04819516T ES2291981T3 ES 2291981 T3 ES2291981 T3 ES 2291981T3 ES 04819516 T ES04819516 T ES 04819516T ES 04819516 T ES04819516 T ES 04819516T ES 2291981 T3 ES2291981 T3 ES 2291981T3
Authority
ES
Spain
Prior art keywords
vitamin
receiver modulators
compounds
modulators
receiver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04819516T
Other languages
English (en)
Inventor
Jianliang Lu
Tainwei Ma
Sunil Nagpal
Quanrong Shen
Alan M. Warshawsky
Ying Kwong Yee
Michael John Rupp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2291981T3 publication Critical patent/ES2291981T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto o una sal farmacéuticamente aceptable del mismo representado mediante la formula, en la que R y R'' son independientemente alquilo C1-C5, fluoroalquilo C1-C5, o conjuntamente R y R'' forman un anillo carbocíclico sustituido o no sustituido, saturado o insaturado que tiene entre 3 y 8 átomos de carbono.
ES04819516T 2003-11-20 2004-11-16 Moduladores del receptor de la vitamina d. Expired - Lifetime ES2291981T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52360003P 2003-11-20 2003-11-20
US523600P 2003-11-20

Publications (1)

Publication Number Publication Date
ES2291981T3 true ES2291981T3 (es) 2008-03-01

Family

ID=34632799

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04819516T Expired - Lifetime ES2291981T3 (es) 2003-11-20 2004-11-16 Moduladores del receptor de la vitamina d.

Country Status (8)

Country Link
US (2) US7582775B2 (es)
EP (1) EP1687292B1 (es)
JP (1) JP4717006B2 (es)
AT (1) ATE370941T1 (es)
CA (1) CA2544522A1 (es)
DE (1) DE602004008505T2 (es)
ES (1) ES2291981T3 (es)
WO (1) WO2005051940A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011903A (es) * 2002-05-29 2005-03-31 Lilly Co Eli Moduladores de receptor de vitamina d tipo fenil-tiofeno.
BR0316401A (pt) 2002-11-22 2006-02-21 Lilly Co Eli composto ou um sal farmaceuticamente aceitável ou um derivado de pró-droga de éster do mesmo, derivados de pró-droga e de sal de um composto, formulações farmacêutica, para tratar a osteoporose, e para tratar psorìase, métodos para tratar um mamìfero para prevenir ou aliviar os efeitos patológicos, para tratar ou previnir estados de doenças mediados pelo receptor de vitamimna d, e para tratar um mamìfero para prevenir ou aliviar o efeito de mostarda, processo para preparar um composto, e, uso de um composto
JP4717005B2 (ja) * 2003-11-20 2011-07-06 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
ES2307069T3 (es) 2003-11-20 2008-11-16 Eli Lilly And Company Compuestos de fenilfurano como moduladores del receptor de la vitamina d.
ES2291981T3 (es) * 2003-11-20 2008-03-01 Eli Lilly And Company Moduladores del receptor de la vitamina d.
WO2005051893A2 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
JP4589336B2 (ja) 2003-11-20 2010-12-01 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
ATE525354T1 (de) * 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
MX2007007225A (es) * 2004-12-21 2007-08-21 Lilly Co Eli Moduladores del receptor de la vitamina d.
ES2322962T3 (es) * 2004-12-21 2009-07-02 Eli Lilly And Company Moduladores del receptor de la vitamina d.
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
EP2040690B1 (en) 2006-06-28 2014-08-06 Sanofi Inhibitors of cxcr2
AU2007264114A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis New CXCR2 inhibitors
WO2008000408A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis Cxcr2 antagonists
WO2008000410A1 (en) 2006-06-30 2008-01-03 Sanofi-Aventis Cxcr2 inhibitors
SG11201706869XA (en) * 2015-03-24 2017-09-28 Shanghai Yingli Pharm Co Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1137733B (de) * 1954-06-05 1962-10-11 Chem Fab Promonta G M B H Verfahren zur Herstellung von Aryl- und Thienylmethylphenylalkylaminen
US5300499A (en) * 1992-09-02 1994-04-05 Allergan, Inc. 5-substituted 3-thiophene sulfonamides as antiglaucoma agents
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
DE19718334A1 (de) * 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Neue Benzylaminderivate und Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1042335A1 (de) * 1997-12-17 2000-10-11 Schering Aktiengesellschaft Vitamin d-derivate mit phosphoratomen in den seitenketten
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6218430B1 (en) * 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
FR2801307B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
MXPA04011903A (es) * 2002-05-29 2005-03-31 Lilly Co Eli Moduladores de receptor de vitamina d tipo fenil-tiofeno.
BR0316401A (pt) 2002-11-22 2006-02-21 Lilly Co Eli composto ou um sal farmaceuticamente aceitável ou um derivado de pró-droga de éster do mesmo, derivados de pró-droga e de sal de um composto, formulações farmacêutica, para tratar a osteoporose, e para tratar psorìase, métodos para tratar um mamìfero para prevenir ou aliviar os efeitos patológicos, para tratar ou previnir estados de doenças mediados pelo receptor de vitamimna d, e para tratar um mamìfero para prevenir ou aliviar o efeito de mostarda, processo para preparar um composto, e, uso de um composto
US20060135484A1 (en) * 2003-01-10 2006-06-22 Eli Lilly And Company Patent Divison Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
WO2004063345A2 (en) * 2003-01-10 2004-07-29 Eli Lilly And Company Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
ATE455749T1 (de) * 2003-10-14 2010-02-15 X Ceptor Therapeutics Inc Verbindungen mit verbrückten ringen als pharmazeutische mittel
JP4717005B2 (ja) * 2003-11-20 2011-07-06 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
JP4589336B2 (ja) * 2003-11-20 2010-12-01 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
ES2291981T3 (es) * 2003-11-20 2008-03-01 Eli Lilly And Company Moduladores del receptor de la vitamina d.
WO2005051893A2 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
ES2307069T3 (es) * 2003-11-20 2008-11-16 Eli Lilly And Company Compuestos de fenilfurano como moduladores del receptor de la vitamina d.
MX2007007225A (es) 2004-12-21 2007-08-21 Lilly Co Eli Moduladores del receptor de la vitamina d.
ES2322962T3 (es) 2004-12-21 2009-07-02 Eli Lilly And Company Moduladores del receptor de la vitamina d.

Also Published As

Publication number Publication date
US7582775B2 (en) 2009-09-01
ATE370941T1 (de) 2007-09-15
US7897789B2 (en) 2011-03-01
EP1687292A2 (en) 2006-08-09
US20100076065A1 (en) 2010-03-25
JP4717006B2 (ja) 2011-07-06
WO2005051940A3 (en) 2005-08-11
EP1687292B1 (en) 2007-08-22
US20070149810A1 (en) 2007-06-28
WO2005051940A2 (en) 2005-06-09
JP2007512329A (ja) 2007-05-17
DE602004008505D1 (de) 2007-10-04
CA2544522A1 (en) 2005-06-09
DE602004008505T2 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
CY1108988T1 (el) Διαμορφωτες υποδοχεα βιταμινης d
CY1109341T1 (el) Διαμορφωτες υποδοχεα βιταμινης d τυπου φαινυλο-θειοφαινιου
ES2291981T3 (es) Moduladores del receptor de la vitamina d.
WO2005051893A3 (en) Vitamin d receptor modulators
DE69911596D1 (de) 24-hydroxy vitamin d, deren analogen und verwendungen
ATE396982T1 (de) Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
MY140767A (en) Compounds, methods and compositions
MX2010002712A (es) Compuestos que modulan calcio intracelular.
ECSP056208A (es) Ligandos del receptor de cannabinoides y usos de los mismos
WO2009076454A3 (en) Compounds that modulate intracellular calcium
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
DE69912598D1 (de) 1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon
WO2005051898A3 (en) Vitamin d receptor modulators
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
AU2003233735A8 (en) 24-sulfoximine vitamin d3 compounds
ES2115267T3 (es) Compuestos de 26,28-metilen-1alfa,25-dihidroxivitamina d2.
EP1539727A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
CY1110326T1 (el) Υποκατασταθεισες τετραλινες και ινδανια και η χρηση τους
EP1576180A4 (en) COMPONENTS OF THE AMPK PATH
WO2004054968A3 (en) 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
WO2022251212A3 (en) Uses of a somatostatin modulator for the treatment of disease
WO2004063348A3 (en) Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
WO2003066666A3 (en) Compositions and methods for treatment of vitamin d deficiency